Mounjaro (tirzepatide) is a GLP-1 and GIP receptor agonist used for type 2 diabetes and weight management in the UK
Our program prescribes medications from the GLP1-RA class, such as Semaglutide, which are widely used, safe, and effective treatments
Eli Lilly maintains that Mochi is peddling the 'personalised line' unfaithfully, instead selling "mass-manufactured, untested, and unapproved one-size fits-all compounded drugs." An Eli Lilly spokesperson told Pharmaceutical Technology : "[The telehealth companies] are deceptively marketing knockoff tirzepatide as safe and effective for 'cosmetic weight loss', improperly practising medicine or influencing medical decisions, and falsely claiming to sell 'personalised' compounded tirzepatide." Mochi Health develops a compounded version of Novo Nordisk's GLP-1RA semaglutide
Semaglutide Phase 3 Results# Semaglutide's weight loss data come from the much larger STEP program: In STEP 1, 86.4% achieved at least 5% weight loss, 69.1% achieved at least 10%, and 50.5% achieved at least 15%
Dubrow called Ozempic "amazing" and "a miracle" but stopped taking it because he wanted to enjoy food again: "I want to be able to eat again because it really took my appetite and all the joy of eating away," Dubrow said